skeletal disease 

New therapies to promote bone healing or treat osteoporosis, arthritis and other skeletal diseases require a comprehensive preclinical assessment of bone and cartilage. Bone endpoints can be incorporated into toxicology programs to fully evaluate test articles that have an intended effect on bone or to determine effects of test articles that have secondary, indirect or adverse effects.

Charles River offers services in the area of bone/skeletal research that combine established discovery and preclinical program development expertise with a host of novel bone research technologies that provide highly specialized evaluations of bone disease and bone quality. Our scientists can assess the effect of a drug in vivo or ex vivo on bone at toxicological and pharmacological doses and facilitate the interpretation of study findings to help you better design clinical trials.

Services

• In vivo preclinical studies
• Bone research
• Routine and specialty dose routes
• Bone and joint pathology
• Clinical assessments
• Research models and services
• Animal models for bone and cartilage evaluations
• Ovariectomy-induced bone loss
• 5/6 nephrectomy model
• TPTx (thyroparathyroidectomy) model
• Periosteal injection
• Schenk model
• Bone defect
• Orthopedic
• Osteoarthritis
• Rheumatoid arthritis
• Formulation development, preparation, and analysis
• Novel surgical techniques
• Radiography
• Bone densitometry
• Biochemical markers of bone turnover
• Preclinical and clinical samples
• Multiple species
• Formation markers
• Resorption markers
• Hormone assays
• Dual-Energy X-Ray Absorptiometry (DXA)
• Peripheral Quantitative Computed Tomography (pQCT)
• Histomorphometry
• Biomechanics
• Micro-CT
• Navigator consulting services
• Laboratory sciences